HZAU Completes Randomized Controlled Trial of Thumbtack Needle for Ovarian Reserve Decline in 240 Patients
Clinical Trial Completion and Design
NCT05277948, a thumbtack needle study sponsored by Dongmei Huang from Dongzhimen Hospital, Affiliated with Tongji Medical College, Huazhong University of Science and Technology in China, was completed on December 6, 2025. A total of 240 women aged 18–40 with diminished ovarian reserve (DOR) were randomly assigned to either an active thumbtack needle group or a sham procedure group in a triple-blind design, with participants, investigators, and assessors blinded. Treatment was administered over two menstrual cycles, and the actual primary outcome completion date was November 28, 2025. Although the protocol describes a multi-center study, ClinicalTrials.gov lists only Dongzhimen Hospital in Wuhan, China, as the conducting site, which should be considered in external validity assessments.
Intervention and Outcome Measures
The thumbtack needle is a medical device intervention involving long-term retention of needles in the skin and is not a pharmaceutical product with a brand name, generic name, or single molecular target. It is also not classified under a Phase of clinical development. Inclusion criteria required patients to meet at least two of the following: anti-Müllerian hormone (AMH) <1.1 ng/mL, antral follicle count (AFC) <7, and follicle-stimulating hormone (FSH) >10 to <25 U/L. The study tracked AMH, FSH, AFC, natural pregnancy rate, oocyte retrieval numbers, fertilization rate, blastocyst formation rate, clinical pregnancy rate, and miscarriage rate in IVF-ET. No results have been submitted to ClinicalTrials.gov, so the completed status does not necessarily indicate efficacy.
Competitive Basis and Standard of Care
For DOR, the clinical competition axis includes assisted reproductive technologies and controlled ovarian stimulation rather than drugs that restore lost follicles. Representative drugs include Gonal-f (folitropin alfa, an FSH receptor agonist) and Menopur (menotropins, an FSH/LH receptor agonist), used in the pathway leading to oocyte retrieval and IVF/ICSI. A separate 120-patient sham-controlled trial showed a pseudo-median difference of 1.00 AFC at 12 weeks (95% CI 0–2.00, p=0.003), but no significant differences at 24 weeks or in AMH/FSH. A 140-patient multi-center trial in a poor responder population also failed to improve oocyte retrieval, clinical pregnancy rate, or live birth rate, making the pregnancy and live birth endpoints in this 240-patient study the key determinants.
Market Potential and Regulatory Context
The global infertility services market is projected to grow from USD 39.88 billion in 2025 to USD 63.36 billion by 2030. The economic opportunity for thumbtack needles lies in adoption as an adjunct service within this market, rather than as an independent pharmaceutical product. In the U.S., the FDA reclassified acupuncture needles from Class III to Class II medical devices on March 29, 1996, and Gonal-f was approved on September 29, 1997. However, this Chinese study is not an FDA-, EMA-, or PMDA-approved trial, nor is it a registration trial directly supporting product approval for DOR. Commercial value will depend on live birth rate improvements, reproducible procedural standardization, and cost-effectiveness compared to existing IVF protocols, rather than surrogate markers like AMH.
From an investment perspective, this study tests the potential for a low-cost adjunctive intervention to enter the USD 39.88 billion global infertility services market in 2025, but its business model is closer to hospital procedural revenue than pharmaceutical patents or royalties. For researchers, the triple-blind, sham-controlled, 240-patient design reduces bias in acupuncture research, but the single registration site and zero result submissions are key limitations. In the industry, Gonal-f and Menopur-based ovarian stimulation and IVF/ICSI remain the competitive standards, with thumbtack needles positioned as complementary rather than alternative. Short-term value hinges on the release of AMH, FSH, and AFC data, while mid-to-long-term adoption depends on significant and reproducible improvements in clinical pregnancy and live birth rates. As a non-pharmaceutical intervention, it is not subject to Phase classification or FDA Advisory Committee (AdComm) processes, and the FDA’s 1996 Class II acupuncture regulation pertains to device distribution, not approval of efficacy for DOR treatment.
Source: ClinicalTrials.gov (api_ct)